TY - JOUR
T1 - The impact of the coronavirus (COVID-19) pandemic on individuals with gastrointestinal disorders
T2 - A protocol of an international collaborative study
AU - Ferreira, Nuno
AU - Mikocka-Walus, Antonina
AU - van Tilburg, Miranda A.L.
AU - Graff, Lesley A.
AU - Apputhurai, Pragalathan
AU - Acosta, Manuel Barreiro de
AU - Evertsz, Floor Bennebroek
AU - Burisch, Johan
AU - Lo, Bobby
AU - Petrik, Megan
AU - Trindade, Inês A.
AU - Jedel, Sharon
AU - Moser, Gabriele
AU - Mokrowiecka, Anna
AU - Bernstein, Charles N.
AU - Dumitrascu, Dan
AU - Ford, Alexander C.
AU - Stengel, Andreas
AU - Gearry, Richard
AU - Knowles, Simon R.
N1 - Funding Information:
Outside of the present work, M Barreiro-de Acosta has served as a speaker, consultant and advisory member for or has received research funding from MSD, AbbVie, Janssen, Kern Pharma, Celltrion, Takeda, Gillead, Celgene, Pfizer, Ferring, Faes Farma, Shire Pharmaceuticals, Dr. Falk Pharma, Chiesi, Gebro Pharma, Adacyte and Vifor Pharma.Outside of the present work, I.A. Trindade received consultancy fees from Pfizer Inc.Outside of the present work Dr. C Bernstein has served on advisory Boards for AbbVie Canada, Amgen Canada, Bristol Myers Squibb Canada, Roche Canada, Janssen Canada, Sandoz Canada, Takeda Canada, and Pfizer Canada; Consultant for Mylan Pharmaceuticals and Takeda; Educational grants from Abbvie Canada, Pfizer Canada, Takeda Canada, and Janssen Canada. Speaker's panel for Abbvie Canada, Janssen Canada, Medtronic Canada, and Takeda Canada. Received research funding from Abbvie Canada and Pfizer Canada.
Funding Information:
Outside of the present work Dr. C Bernstein has served on advisory Boards for AbbVie Canada, Amgen Canada, Bristol Myers Squibb Canada, Roche Canada, Janssen Canada, Sandoz Canada, Takeda Canada, and Pfizer Canada; Consultant for Mylan Pharmaceuticals and Takeda; Educational grants from Abbvie Canada, Pfizer Canada, Takeda Canada, and Janssen Canada. Speaker's panel for Abbvie Canada, Janssen Canada, Medtronic Canada, and Takeda Canada. Received research funding from Abbvie Canada and Pfizer Canada .
Publisher Copyright:
© 2021 Elsevier Inc.
PY - 2021/9
Y1 - 2021/9
N2 - Objective: The COVID-19 pandemic has had a significant impact on mental health across the globe. People living with a chronic gastrointestinal (GI) disorder might be particularly at risk of mental health complications given higher rates of comorbid anxiety and depression compared to the healthy population. As GI disorders affect up to 40% of the population worldwide, this international collaborative study seeks to evaluate the extent of the impact of the COVID-19 pandemic on GI symptoms specifically and more generally on the well-being of those living with chronic GI conditions. Methods: A longitudinal survey with three time points (baseline, 6-month, and 12-month) will be conducted online. Adult participants with GI disorders from multiple countries will be recruited via patient associations, social media advertising, utilizing snowball sampling. Participants will be invited to complete a battery of questionnaires including demographic and health parameters, and measures of gastrointestinal symptoms, fear of COVID-19, perceived impact of COVID-19, illness perceptions, coping, depression, anxiety, stress, catastrophizing, and quality of life, using validated measures where available. Statistical analyses will include univariate descriptive models, multivariate models utilizing regression, mediation, and moderation, and latent growth models. Conclusions: This project may present novel information to the field of psychogastroenterology and may provide crucial information regarding the areas of impact for individuals with GI disorders during and following the pandemic. Further, this information can guide healthcare providers and patient associations on how to target support related to the pandemic mental health sequelae for these patients.
AB - Objective: The COVID-19 pandemic has had a significant impact on mental health across the globe. People living with a chronic gastrointestinal (GI) disorder might be particularly at risk of mental health complications given higher rates of comorbid anxiety and depression compared to the healthy population. As GI disorders affect up to 40% of the population worldwide, this international collaborative study seeks to evaluate the extent of the impact of the COVID-19 pandemic on GI symptoms specifically and more generally on the well-being of those living with chronic GI conditions. Methods: A longitudinal survey with three time points (baseline, 6-month, and 12-month) will be conducted online. Adult participants with GI disorders from multiple countries will be recruited via patient associations, social media advertising, utilizing snowball sampling. Participants will be invited to complete a battery of questionnaires including demographic and health parameters, and measures of gastrointestinal symptoms, fear of COVID-19, perceived impact of COVID-19, illness perceptions, coping, depression, anxiety, stress, catastrophizing, and quality of life, using validated measures where available. Statistical analyses will include univariate descriptive models, multivariate models utilizing regression, mediation, and moderation, and latent growth models. Conclusions: This project may present novel information to the field of psychogastroenterology and may provide crucial information regarding the areas of impact for individuals with GI disorders during and following the pandemic. Further, this information can guide healthcare providers and patient associations on how to target support related to the pandemic mental health sequelae for these patients.
KW - Anxiety
KW - COVID-19
KW - Depression
KW - Gastrointestinal disorders
KW - Mental health
KW - Quality of life
KW - Stress
UR - http://www.scopus.com/inward/record.url?scp=85109454554&partnerID=8YFLogxK
U2 - 10.1016/j.jpsychores.2021.110561
DO - 10.1016/j.jpsychores.2021.110561
M3 - Article
AN - SCOPUS:85109454554
SN - 0022-3999
VL - 148
JO - Journal of Psychosomatic Research
JF - Journal of Psychosomatic Research
M1 - 110561
ER -
